



## Dicerna to Report Fourth Quarter and Year End 2018 Financial Results and Host Conference Call on March 11, 2019

March 4, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 4, 2019-- [Dicerna Pharmaceuticals, Inc.](#) (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its fourth quarter and year end 2018 financial results after market close on Monday, March 11, 2019.

Management will host a conference call at 4:30 p.m. ET that day to discuss the Company's financial results and provide a general business update. A live audio webcast will be available on the "Investors & Media" section of the Dicerna website, [www.investors.dicerna.com](http://www.investors.dicerna.com). The webcast will also be archived on the Company's website.

The call can also be accessed by dialing (855) 453-3834 or (484) 756-4306 (international) and referencing conference ID 3386549 prior to the start of the call. After the conference call, a replay will be available for seven days. To access the replay, please dial (855) 859-2056 or (404) 537-3406 and refer to conference ID 3386549.

### About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for the treatment of diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases and viral infectious diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. Dicerna has strategic collaborations with Eli Lilly and Company, Alexion Pharmaceuticals, Inc. and Boehringer Ingelheim International GmbH. For more information, please visit [www.dicerna.com](http://www.dicerna.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190304005955/en/>

Source: Dicerna Pharmaceuticals, Inc.

Rebecca Peterson  
Head of Corporate Communications  
Dicerna Pharmaceuticals, Inc.  
Ph: 617-612-6235  
[rpeterson@dicerna.com](mailto:rpeterson@dicerna.com)